HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, has appointed Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. The appointment comes as the company prepares for the limited launch of its recently cleared HeartBeam System, which represents a significant advancement in portable cardiac monitoring technology.
In his newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives. This includes overseeing the limited launch of the HeartBeam System for arrhythmia assessment and heart attack detection indication, along with a 12-lead ECG extended wear patch monitor. His responsibilities will also involve expanding outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption of the technology.
The importance of this appointment lies in the transformative potential of HeartBeam's technology. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care—all outside of a medical facility.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-Lead ECG synthesis software receiving clearance in December 2025. The company's cleared indications for use are detailed at https://www.heartbeam.com/indications. This regulatory approval represents a critical milestone that enables commercial deployment of technology that could redefine cardiac health management by moving detection and monitoring outside traditional clinical settings.
The commercial implications are substantial for both the healthcare industry and patients. By enabling remote cardiac monitoring with hospital-grade accuracy, the technology could reduce unnecessary emergency room visits, enable earlier intervention for cardiac events, and provide continuous monitoring for at-risk patients. For the medical technology sector, HeartBeam's approach represents a shift toward more accessible, patient-centered cardiac care solutions that leverage advanced signal processing and portable hardware.
Humbarger's appointment signals HeartBeam's transition from development to commercialization phase, with his experience expected to accelerate market adoption of technology that has received significant regulatory validation. The company's progress and updates are available in its newsroom at https://ibn.fm/BEAT. As cardiac disease remains a leading cause of mortality worldwide, technologies that improve detection and monitoring outside clinical settings could have profound impacts on patient outcomes and healthcare system efficiency.
